NAGE:NASDAQNiagen Bioscience, Inc. Analysis

Niagen Bioscience (NAGE) is trading at $3.67, just above its calculated support of $3.60, indicating limited downside cushion. The 20‑day and 50‑day SMAs (4.42 and 4.55) sit well above the current price, confirming a bearish price trend. Technical momentum is weak, with a MACD histogram of –0.10 and an RSI of 29.9, suggesting the stock is oversold but still under pressure. High beta (≈1.73) and a 30‑day volatility of over 65% amplify price swings.
Fundamentally, the company posted $130.4 M in revenue with a 3.3 % YoY growth, and margins remain robust (gross margin 64 %, operating margin 5 %). Return on equity stands at 27 % and the balance sheet is strong, featuring $66.4 M of cash against only $2.6 M of debt. EPS is expected to rise from $0.21 trailing to $0.32 forward, driving the forward P/E down to ~11.5, well below the industry average of 27.2. Analysts (5) rate the stock a “strong buy” with a median price target of $12, implying a potential upside of more than 200 %.
Recent material news reinforces the upside narrative: management reaffirmed a 10‑15 % growth outlook for 2026 while increasing marketing spend, and a new partnership with Olympia expands the pharmaceutical‑grade Niagen supply chain. Q1 results showed net sales of $31.5 M, gross margin improvement to 63.5 %, and net income of $6.3 M, beating expectations. These catalysts, combined with a low dividend payout (none) and a DCF fair value of $1.38, suggest the market may be pricing in speculative optimism. Consequently, the short‑term recommendation is to hold pending a bounce off support, while medium‑ and long‑term outlooks favor buy positions.